Gladstone Institutes Team Evaluates NGS to Monitor Drug Resistance in HIV Patients | GenomeWeb

Researchers at the Gladstone Institutes and the University of California, San Francisco are evaluating next-generation sequencing for its ability to detect early signs of drug resistance in HIV patients.

In an Illumina-sponsored webinar, Gordon Bentley, a senior research associate at the Gladstone Institute of Virology and Immunology, discussed his group's use of deep amplicon sequencing of the HIV reverse transcriptase gene to look for known mutations conferring resistance to antiretroviral drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.